Recce Pharmaceuticals Appoints Alistair McKeough to Board of Directors
SYDNEY Australia, 1 September 2022: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a New Class of Synthetic Anti-infectives, is pleased to announce, in accordance with ASX Listing Rule 3.16.1, the appointment of Alistair McKeough as Non-Executive Director and Maggie Niewidok as Company Secretary, effective today.
Alistair is a solicitor with extensive operational and board experience in many sectors, including professional services, technology, biotechnology, financial services, education and charities. He was formerly Head of Professional Services at Automic Group, which acquired his legal, company secretarial and corporate governance business, Whittens & McKeough, in 2018. Alistair was Managing Director of the firm at that time. He is currently the Chair of the Waratah Education Foundation.
Alistair has had deep leadership experience in many high performing companies, in which he has had responsibility for a range of organisational performance outcomes including safety and risk management, corporate governance, legal compliance, cost reduction, strategy, change management, M&A, capital raising, culture and value creation.
Alistair has immediately stepped out of the company secretary role to become a director of Recce, having served as Recce Pharmaceuticals’ Company Secretary and primary legal adviser from 29 November 2017 to 31 August 2022. The board now welcomes Alistair’s governance and legal expertise in the role of non-executive director. Alistair will also assume the role of Chair of the Company’s Audit & Risk Management Committee.
Maggie Niewidok takes on the role of Company Secretary. Maggie is an experienced solicitor and company secretary who has worked across a broad industry base of ASX listed companies. For the purposes of ASX Listing Rule 12.6, Ms Niewidok will be the person responsible for communications between the Company and ASX.
Recce Pharmaceuticals Chairman Dr John Prendergast said, “Strengthening the corporate governance of the Board has been an area of key focus of mine as the Company’s infectious disease programs move ahead and become institutionally relevant, locally and overseas. The board and I are delighted to welcome Alistair as a non-executive director. He knows the Company well, is excited about the future for Recce and brings deep insights into Australia’s financial, corporate and regulatory environments. I’m also delighted to welcome Maggie as Company Secretary. She has worked with the company for much of this year and is extremely capable. On behalf of the board and shareholders, I welcome Alistair and Maggie and look forward to their contributions.”
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
